These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17449210)

  • 41. Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration.
    Fernández-Varón E; Bovaira MJ; Espuny A; Escudero E; Vancraeynest D; Cárceles CM
    J Vet Pharmacol Ther; 2005 Aug; 28(4):343-8. PubMed ID: 16050813
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Flouroquinolone activity in clinical isolates of Streptococcus pneumoniae with different susceptibility to penicilline: an epidemiological study in five cities of Mexico].
    Calva-Mercado JJ; Castillo G; López-Vidal Y
    Gac Med Mex; 2005; 141(4):253-8. PubMed ID: 16164118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
    Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum bactericidal activity of the methoxyfluoroquinolones gatifloxacin and moxifloxacin against clinical isolates of Staphylococcus species: are the susceptibility breakpoints too high?
    Stein GE; Schooley S; Kaatz GW
    Clin Infect Dis; 2003 Nov; 37(10):1392-5. PubMed ID: 14583876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Levofloxacin versus azithromycin on the oropharyngeal carriage and selection of antibacterial- resistant streptococci in the microflora of healthy adults.
    Nord CE; Peterson J; Ambruzs M; Fisher AC
    Curr Med Res Opin; 2009 Jun; 25(6):1461-7. PubMed ID: 19419343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
    Czock D; Hüsig-Linde C; Langhoff A; Schöpke T; Hafer C; de Groot K; Swoboda S; Kuse E; Haller H; Fliser D; Keller F; Kielstein JT
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1263-8. PubMed ID: 17699357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Laguna B; Echeverría O; Carcas A; Lubomirov R; Casal J; Prieto J
    J Antimicrob Chemother; 2005 May; 55(5):742-7. PubMed ID: 15761068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.
    Taubel J; Naseem A; Harada T; Wang D; Arezina R; Lorch U; Camm AJ
    Br J Clin Pharmacol; 2010 Apr; 69(4):391-400. PubMed ID: 20406223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bactericidal activity of levofloxacin against Streptococcus pneumoniae in an in-vitro model simulating serum pharmacokinetic parameters.
    Shah PM; Schwärzel R
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():71-5. PubMed ID: 10404342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Streptococcus pneumoniae: susceptibility to penicillin and moxifloxacin.
    Rossi F; Franco MR; Rodrigues HM; Andreazzi D
    J Bras Pneumol; 2012; 38(1):66-71. PubMed ID: 22407042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Yokota S; Ohkoshi Y; Fujii N
    Diagn Microbiol Infect Dis; 2009 Sep; 65(1):76-80. PubMed ID: 19679241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers.
    Wagenlehner FM; Kees F; Weidner W; Wagenlehner C; Naber KG
    Int J Antimicrob Agents; 2008 Jan; 31(1):21-6. PubMed ID: 18054465
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
    Wagner RS; Abelson MB; Shapiro A; Torkildsen G
    Arch Ophthalmol; 2005 Sep; 123(9):1282-3. PubMed ID: 16157821
    [No Abstract]   [Full Text] [Related]  

  • 56. Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones.
    Malerczyk C; Kolbert M; Kinzig-Schippers M; Sörgel F; Machka K; Shah PM
    J Chemother; 2004 Feb; 16(1):56-61. PubMed ID: 15078000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.
    Li X; Zhao X; Drlica K
    Antimicrob Agents Chemother; 2002 Feb; 46(2):522-4. PubMed ID: 11796368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
    Singh R; Ledesma KR; Chang KT; Hou JG; Prince RA; Tam VH
    J Antimicrob Chemother; 2009 Sep; 64(3):556-62. PubMed ID: 19589810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
    Kim SY; Lim JA; Choi JS; Choi EC; Joo CK
    Cornea; 2007 Jul; 26(6):720-5. PubMed ID: 17592324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bactericidal activity of moxifloxacin against pneumococci.
    Levy D; Berche P
    Clin Microbiol Infect; 2001 Jan; 7(1):47-8. PubMed ID: 11284948
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.